


Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound represented by Formula (1):

[Formula 1]



wherein Cy is a phenyl ~~an aromatic hydrocarbon group which may be substituted, or an aromatic heterocyclic group which may be substituted~~ with a halogen atom or a C₂₋₄ alkylene; R¹ is a hydrogen atom ~~or a hydrocarbon group which may be substituted~~; V is -C(O)-, -S(O)-, or -S(O)₂-; W is -NH- (R²)-, -O-, or a bond ~~(wherein R² is a hydrogen atom or a hydrocarbon group which may be substituted)~~; X is a methylene alkylene which may be substituted with (1) a C₁₋₆ alkyl, (2) a C₂₋₆ alkenyl, (3) a C₂₋₆ alkynyl, (4) a phenyl, (5) a C₃₋₇ cycloalkyl, (6) a C₃₋₆ cycloalkenyl, (7) a C₇₋₁₆ aralkyl or (8) a 5- to 6-membered aromatic monocyclic heterocyclic group, where each of the C₁₋₆ alkyl of (1), the C₂₋₆ alkenyl of (2), the C₂₋₆ alkynyl of (3), the phenyl of (4), the C₃₋₇ cycloalkyl of (5), the C₃₋₆ cycloalkenyl of (6), the C₇₋₁₆ aralkyl of (7) and the 5- to 6-membered aromatic monocyclic heterocyclic group of (8) may be substituted with (i) a hydroxyl group, (ii) a thiol group which may be substituted with C₁₋₆ alkyl, (iii) a carboxyl, (iv) a C₁₋₆ alkoxy carbonyl, (v) an acyl, (vi) an amino which may be substituted with lower alkyl, carboxyl, C₁₋₆ alkoxy carbonyl or acyl, (vii) a halogen atom, (viii) a carbamoyloxy, (ix) a nitro group, (x) a cyano group, (xi) a lower alkyl which may be substituted with 1 to 5 halogen atoms, (xii) a phenyl which may be substituted with 1 to 5 halogen atoms, (xiii) a lower alkoxy which may be substituted with a phenyl or 1 to 5 halogen atoms, (xiv) a 5- to 6-membered aromatic monocyclic heterocyclic group or (xv) a thioxo; Y is -C(O)-, -S(O)-, or -S(O)₂-; Z is a bond or a C₁₋₆ alkylene, a chain hydrocarbon group which may be substituted, or -N=; ring A is a piperadine ring which may be substituted, or a piperazine ring which may be substituted; non-

~~aromatic nitrogen-containing heterocyclic ring which may be substituted; and ring B is a piperazine ring which may be substituted, an imidazoline ring which may be substituted, an imidazole ring which may be substituted, a thiazoline ring which may be substituted, or a fused nitrogen-containing heterocyclic ring which may be substituted; and~~

~~----- , -----~~

~~is each independently a single bond or a double bond; R^1 and R^2 may be bonded to each other to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; and R^2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted, or a salt thereof.~~

2-3. (Canceled)

4. (Currently Amended) The compound according to claim 1, wherein Cy is a phenyl which may be substituted with a halogen atom.

5-14. (Canceled)

15. (Original) The compound according to claim 1, wherein ring B is a fused nitrogen-containing heterocyclic ring which may be substituted.

16. (Currently Amended) The compound according to claim 15, wherein the fused nitrogen-containing heterocyclic ring is a fused pyridine ring which may be substituted, a fused imidazole ring which may be substituted, a fused pyrazole ring which may be substituted, or a fused thiazoline ring which may be substituted.

17. (Canceled)

18. (Original) A compound selected from the group consisting of N-(4-chlorophenyl)-N'-((1R)-2,2-dimethyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, N-(4-chlorophenyl)-N'-(2-ethyl-2-hydroxy-1-((4-(5-methyl-3-

oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)butyl)urea, N-(4-chlorophenyl)-N'-((1S)-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)-2-(methylthio)propyl)urea, and N-(4-chlorophenyl)-N'-(2-methoxy-2-methyl-1-((4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperazinyl)carbonyl)propyl)urea, or a salt thereof.

19. (Previously presented) A pharmaceutical composition comprising the compound according to claim 1.

20-23. (Canceled)

24. (Currently Amended) A method of inhibiting blood coagulation in mammal which comprises administering an effective amount of the compound according to claim 1 ~~or a prodrug thereof~~ to the mammal.

25. (Currently Amended) A method of inhibiting activated blood coagulation factor X in mammal which comprises administering an effective amount of the compound according to claim 1 ~~or a prodrug thereof~~ to the mammal.

26. (Currently Amended) A method of preventing and/or treating myocardial infarction, cerebral infarction, deep vein thrombosis, pulmonary thromboembolism or arteriosclerosis obliterans in mammal which comprises administering an effective amount of the compound according to claim 1 ~~or a prodrug thereof~~ to the mammal.

27-30. (Canceled)

31. (New) The compound according to claim 1, wherein

----- , -----

are both single bonds.